Zander Therapeutics, Inc
company.status.inactiveCIK 1718644fmd_1DMWD72Q0CCN8Z8SNQVHMR4XGRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2016 to Sep 30, 2019, 10 periods
Latest annual · FY2019
Millions- Operating income
- (2)
- Net income
- 0
Latest quarter · Q1 FY2020
Millions- Operating income
- (0)
- Net income
- (2)
Zander Therapeutics, Inc financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Operating income | -$1.8 million | -$2.2 million | 10-K 2019-08-30 · proof | |
| Net income | $308,516 | -$2.2 million | 10-K 2019-08-30 · proof | |
| Cash from operating activities | -$1.2 million | -$1.1 million | 10-K 2019-08-30 · proof | |
| Total assets | $2.7 million | $472,202 | +464.9% | 10-K 2019-08-30 · proof |
| Total liabilities | $1.9 million | $1.1 million | +72.7% | 10-K 2019-08-30 · proof |
| Cash and cash equivalents | $28,124 | $370,313 | -92.4% | 10-K 2019-08-30 · proof |
- What was Zander Therapeutics, Inc's operating income in fiscal 2019?
- Zander Therapeutics, Inc reported operating income of -$1.8 million for fiscal 2019 (the year ended Jun 30, 2019), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
- What was Zander Therapeutics, Inc's net income in fiscal 2019?
- Zander Therapeutics, Inc reported net income of $308,516 for fiscal 2019 (the year ended Jun 30, 2019), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
- What was Zander Therapeutics, Inc's cash from operating activities in fiscal 2019?
- Zander Therapeutics, Inc reported cash from operating activities of -$1.2 million for fiscal 2019 (the year ended Jun 30, 2019), against -$1.1 million the year before. Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
- What are Zander Therapeutics, Inc's total assets?
- As of Jun 30, 2019, Zander Therapeutics, Inc reported total assets of $2.7 million, against $472,202 a year earlier (+464.9%). Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
- What are Zander Therapeutics, Inc's total liabilities?
- As of Jun 30, 2019, Zander Therapeutics, Inc reported total liabilities of $1.9 million, against $1.1 million a year earlier (+72.7%). Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
- What are Zander Therapeutics, Inc's cash and cash equivalents?
- As of Jun 30, 2019, Zander Therapeutics, Inc reported cash and cash equivalents of $28,124, against $370,313 a year earlier (-92.4%). Source: the 10-K filed with the SEC on Aug 30, 2019. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1718644&period_type=annual&limit=5"Information only, not investment advice.